Autologous CAR T cell manufacturing using a semiautomatic, closed, modular workflow

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several US FDA-approved products already on the market. There has been tremendous effort to make CAR-T cells more effective, safe and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation and contamination can be associated with open processes and manual handling of CAR-T cells. 

Cell isolation, gene editing, expansion and cryopreservation are complex steps in a typical autologous CAR-T cell manufacturing process. Integrating this complicated multistep workflow into a closed, modular, benchtop system can facilitate a transition from the laboratory to clinical manufacturing while improving consistency, purity and safety.  

In this review, Thermo Fisher Scientific (CA, USA) presents a digitally compatible, GMP-compliant, semiautomated manufacturing platform, which when used with Gibco™ CTS™ reagents, protocols and analytics, can result in consistent, efficacious CAR-T cell production. The system leverages the DeltaV™ Distributed Control System from Emerson to control and manage the instruments in the workflow. 

This content was supplied by Thermo Fisher Scientific.